Astellas seeks new Xtandi indication

Share this article:

Astellas and Medivation have made pursuit of a pre-chemo indication for Xtandi official: the two companies announced Tuesday that they have filed a supplemental New Drug Application with the FDA so the oral drug can be used by metastatic castration-resistant prostate cancer patients earlier in treatment.

The drug is currently approved for patients who have already received docetaxel. The companies released the Phase-III data that is the basis of Tuesday's submission in January. The data indicated that an earlier intervention bought patients progression-free time.

Phase-III results also indicated that prostate-specific antigen levels fell by at least 50% among 75% of the test group, and overall survival was 29% greater with pre-chemo use compared to placebo.

Adding a pre-chemo indication to a post-chemo drug is not a new strategy: Roche moved its breast cancer drug Perjeta into first-line treatment for early stage breast cancer patients in September.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters